Sanofi (SNYNF – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham Parry from Bank ...

Sanofi’s SNY stock has declined 10.2% in the past three months. However, a lot of this price decline was due to the downtrend of the overall drug and biotech sector, which performed poorly in the past ...

Sanofi’s Dupixent and new drugs drive growth, despite near-term pressures. See why SFY stock’s product pipeline makes it a ...

After hitting a regulatory roadblock in 2022, Sanofi’s consumer healthcare business Opella has secured the FDA’s blessing to ...

ranks 4th on our list of the best European stocks. Sanofi (NASDAQ:SNY), a Paris-based global healthcare company, develops and markets pharmaceuticals, vaccines, and consumer healthcare products.

Dupixent: A Key Top-Line Driver for SNY Sanofi’s immunology ... backed by its innovation efforts. Sanofi’s new products like novel recombinant factor VIII therapy, Altuviiio, respiratory ...